Genetic and blood markers to predict PAH treatment response
Genomic and Circulating Predictors of PAH response
This project looks at whether genetic and blood-based markers can help doctors choose the PAH treatments most likely to help you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11322677 on NIH RePORTER |
What this research studies
You would provide blood and DNA samples and clinical information so investigators can study genetic, RNA, and circulating protein signals linked to how people with pulmonary arterial hypertension respond to different drugs. The team is building on earlier work that found RNA patterns and DNA variants mark people who do well on calcium channel blockers and is now also searching for markers tied to big responses to parenteral prostacyclin. They use genomic analyses, polygenic risk scores, and other 'omics' methods and compare those findings with real treatment responses. The aim is to create tests that guide treatment choice and reduce trial-and-error prescribing.
Who could benefit from this research
Good fit: Adults diagnosed with pulmonary arterial hypertension, especially those being considered for calcium channel blocker or parenteral prostacyclin therapy, are the ideal candidates.
Not a fit: People without pulmonary arterial hypertension or those whose disease does not carry the studied genetic or blood markers are unlikely to benefit directly from the findings.
Why it matters
Potential benefit: If successful, this could help match patients to the PAH drug class most likely to work for them, improving outcomes and avoiding ineffective treatments.
How similar studies have performed: Previous work by these investigators and others has shown RNA expression patterns and DNA variants can identify calcium channel blocker responders, while predictors for prostacyclin response are newer and less established.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Hemnes, Anna R — Vanderbilt University Medical Center
- Study coordinator: Hemnes, Anna R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.